REPLIGEN CORP (RGEN)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for RGEN
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| RGEN | Chief Technology Officer; Director | 68 | ["Risk Oversight", "Manufacturing & Global Operations", "Strategic Planning and M&A", "Chief Technology Officer at Ring Therapeutics", "Operating Partner at Flagship Pioneering", "Former Chief Technology Officer at Codiak BioSciences", "Experience at Sanofi's Boston hub in bioprocess and technology development", "Former Head of Process Sciences at Bayer", "Published 60 peer-reviewed papers", "More than 15 patents and patent applications", "Experience in development and commercialization of biotechnology products"] | ["Nominating & Corporate Governance"] | 2026 |
Biography sourced from the proxy statement filing.
Member of the Nominating and Corporate Governance Committee. The Board has determined that Dr. Konstantinov is independent within the meaning of the SEC's and Nasdaq's director independence standards.